Peter Nash1, Iain B McInnes2, Philip J Mease3, Howard Thom4, Matthias Hunger5, Andreas Karabis6, Kunal Gandhi7, Shephard Mpofu8, Steffen M Jugl8. 1. University of Queensland, Brisbane, QLD, Australia. drpnash@tpg.com.au. 2. University of Glasgow, Glasgow, UK. 3. Swedish Medical Center and University of Washington, Seattle, WA, USA. 4. University of Bristol, Bristol, UK. 5. MAPI Group, Munich, Germany. 6. MAPI Group, Houten, The Netherlands. 7. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 8. Novartis Pharma AG, Basel, Switzerland.
Abstract
INTRODUCTION:Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations. METHODS: Individual patient data from the FUTURE 2 RCT (secukinumab vs. placebo; N = 299) were adjusted to match baseline characteristics of the ADEPT RCT (adalimumab vs. placebo; N = 313). Logistic regression determined adjustment weights for age, body weight, sex, race, methotrexate use, psoriasis affecting ≥ 3% of body surface area, Psoriasis Area and Severity Index score, Health Assessment Questionnaire Disability Index score, presence of dactylitis and enthesitis, and previous anti-TNF therapy. Recalculated secukinumab outcomes were compared with adalimumab outcomes at weeks 12 (placebo-adjusted), 16, 24, and 48 (nonplacebo-adjusted). RESULTS: After matching, the effective sample size for FUTURE 2 was 101. Week 12 American College of Rheumatology (ACR) response rates were not significantly different between secukinumab and adalimumab. Week 16 ACR 20 and 50 response rates were higher for secukinumab 150 mg than for adalimumab (P = 0.017, P = 0.033), as was ACR 50 for secukinumab 300 mg (P = 0.030). Week 24 ACR 20 and 50 were higher for secukinumab 150 mg than for adalimumab (P = 0.001, P = 0.019), as was ACR 20 for secukinumab 300 mg (P = 0.048). Week 48 ACR 20 was higher for secukinumab 150 and 300 mg than for adalimumab (P = 0.002, P = 0.027), as was ACR 50 for secukinumab 300 mg (P = 0.032). CONCLUSIONS: In our analysis, patients with PsA receiving secukinumab were more likely to achieve higher ACR responses through 1 year (weeks 16-48) than those treated with adalimumab. Although informative, these observations rely on a subgroup of patients from FUTURE 2 and thus should be considered interim until the ongoing head-to-head RCT EXCEED can validate these findings. FUNDING: Novartis Pharma AG.
RCT Entities:
INTRODUCTION:Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations. METHODS: Individual patient data from the FUTURE 2 RCT (secukinumab vs. placebo; N = 299) were adjusted to match baseline characteristics of the ADEPT RCT (adalimumab vs. placebo; N = 313). Logistic regression determined adjustment weights for age, body weight, sex, race, methotrexate use, psoriasis affecting ≥ 3% of body surface area, Psoriasis Area and Severity Index score, Health Assessment Questionnaire Disability Index score, presence of dactylitis and enthesitis, and previous anti-TNF therapy. Recalculated secukinumab outcomes were compared with adalimumab outcomes at weeks 12 (placebo-adjusted), 16, 24, and 48 (nonplacebo-adjusted). RESULTS: After matching, the effective sample size for FUTURE 2 was 101. Week 12 American College of Rheumatology (ACR) response rates were not significantly different between secukinumab and adalimumab. Week 16 ACR 20 and 50 response rates were higher for secukinumab 150 mg than for adalimumab (P = 0.017, P = 0.033), as was ACR 50 for secukinumab 300 mg (P = 0.030). Week 24 ACR 20 and 50 were higher for secukinumab 150 mg than for adalimumab (P = 0.001, P = 0.019), as was ACR 20 for secukinumab 300 mg (P = 0.048). Week 48 ACR 20 was higher for secukinumab 150 and 300 mg than for adalimumab (P = 0.002, P = 0.027), as was ACR 50 for secukinumab 300 mg (P = 0.032). CONCLUSIONS: In our analysis, patients with PsA receiving secukinumab were more likely to achieve higher ACR responses through 1 year (weeks 16-48) than those treated with adalimumab. Although informative, these observations rely on a subgroup of patients from FUTURE 2 and thus should be considered interim until the ongoing head-to-head RCT EXCEED can validate these findings. FUNDING: Novartis Pharma AG.
Authors: James E Signorovitch; Vanja Sikirica; M Haim Erder; Jipan Xie; Mei Lu; Paul S Hodgkins; Keith A Betts; Eric Q Wu Journal: Value Health Date: 2012 Sep-Oct Impact factor: 5.725
Authors: James E Signorovitch; Eric Q Wu; Andrew P Yu; Charles M Gerrits; Evan Kantor; Yanjun Bao; Shiraz R Gupta; Parvez M Mulani Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981
Authors: S Fénix-Caballero; E J Alegre-del Rey; R Castaño-Lara; F Puigventós-Latorre; J M Borrero-Rubio; J F López-Vallejo Journal: J Clin Pharm Ther Date: 2013-04-17 Impact factor: 2.512
Authors: Mark C Genovese; Philip J Mease; Glen T D Thomson; Alan J Kivitz; Renee J Perdok; Mark A Weinberg; John Medich; Eric H Sasso Journal: J Rheumatol Date: 2007-04-15 Impact factor: 4.666
Authors: Iain B McInnes; Joachim Sieper; Jürgen Braun; Paul Emery; Désirée van der Heijde; John D Isaacs; Georg Dahmen; Jürgen Wollenhaupt; Hendrik Schulze-Koops; Joseph Kogan; Shenglin Ma; Martin M Schumacher; Arthur P Bertolino; Wolfgang Hueber; Paul P Tak Journal: Ann Rheum Dis Date: 2013-01-29 Impact factor: 19.103
Authors: Philip Mease; Ernest Choy; Peter Nash; Chrysostomos Kalyvas; Matthias Hunger; Luminita Pricop; Kunal K Gandhi; Steffen M Jugl; Howard Thom Journal: Eur J Rheumatol Date: 2018-07-01
Authors: Philip J Mease; Josef S Smolen; Frank Behrens; Peter Nash; Soyi Liu Leage; Lingnan Li; Hasan Tahir; Melinda Gooderham; Eswar Krishnan; Hong Liu-Seifert; Paul Emery; Sreekumar G Pillai; Philip S Helliwell Journal: Ann Rheum Dis Date: 2019-09-28 Impact factor: 19.103
Authors: Amir Haddad; Tal Gazitt; Ilan Feldhamer; Joy Feld; Arnon Dov Cohen; Idit Lavi; Faten Tatour; Irena Bergman; Devy Zisman Journal: Arthritis Res Ther Date: 2021-01-29 Impact factor: 5.156
Authors: B Fautrel; B Zhu; P C Taylor; M van de Laar; P Emery; F De Leonardis; C L Kannowski; C Nicolay; Z Kadziola; I De La Torre; R Fleischmann Journal: RMD Open Date: 2020-04
Authors: Walter P Maksymowych; Vibeke Strand; Peter Nash; Yusuf Yazici; Howard Thom; Matthias Hunger; Chrysostomos Kalyvas; Kunal K Gandhi; Brian Porter; Steffen M Jugl Journal: Eur J Rheumatol Date: 2018-10-30